Climb Cash from 2010 to 2024

CLYM Stock   1.95  0.08  3.94%   
Climb Bio Cash yearly trend continues to be very stable with very little volatility. Cash is likely to drop to about 56.1 M. Cash is the total amount of money in the form of currency that Climb Bio has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
2010-12-31
Previous Quarter
93.1 M
Current Value
56.1 M
Quarterly Volatility
20.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 16.1 M, Total Revenue of 0.0 or Research Development of 20.4 M, as well as many indicators such as . Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
  
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.

Latest Climb Bio's Cash Growth Pattern

Below is the plot of the Cash of Climb Bio over the last few years. Cash refers to the most liquid asset of Climb Bio, which is listed under current asset account on Climb Bio balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Climb Bio customers. The amounts must be unrestricted with restricted cash listed in a different Climb Bio account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Climb Bio's Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Climb Bio's overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Climb Cash Regression Statistics

Arithmetic Mean31,007,010
Geometric Mean26,936,716
Coefficient Of Variation67.41
Mean Deviation15,429,348
Median20,487,000
Standard Deviation20,902,873
Sample Variance436.9T
Range72.6M
R-Value0.69
Mean Square Error244.8T
R-Squared0.48
Significance0
Slope3,237,411
Total Sum of Squares6117T

Climb Cash History

202456.1 M
202393.1 M
202243.6 M
202146.9 M

About Climb Bio Financial Statements

Climb Bio investors utilize fundamental indicators, such as Cash, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash93.1 M56.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.